Abiopharma

On December 16, 2022, Trinity Resources Inc. announced it has applied for name and symbol change to reflect its new name of ALZEX NEUROPHARMA INC. and is awaiting final approval from FINRA of its Corporate Action. On June 30, 2022, the Company entered into an asset purchase agreement to purchase the assets and intellectual property of Alzex Biomedical Group Inc. ("Alzex Bio"), a company incorporated under the laws of the Province of British Columbia, Canada. The purchase price was 10,000,000 restricted shares of our Series A and Series B Convertible Preferred Stock, which were subsequently issued on August 5, 2022. The Company will also advance the sum of $150,000 to Alzex Bio to be disbursed with mutual agreement for settlement of certain outstanding liabilities of Alzex Bio as well as to further secure, and refile where warranted, additional patent protection covering the intellectual property. Under the terms of the asset purchase agreement, the shareholders of the Companys Series A and Series B Convertible Preferred Stock will retain security over the intellectual property until we have successfully raised the first five million dollars ($5,000,000 USD) for deployment towards the clinical development of the acquired Alzex Bio assets, at which point the preferred shares will automatically convert to common shares.

Additional info from OTC:
On December 16, 2022, Trinity Resources Inc. announced it has applied for name and symbol change to reflect its new name of ALZEX NEUROPHARMA INC. and is awaiting final approval from FINRA of its Corporate Action. On June 30, 2022, the Company entered into an asset purchase agreement to purchase the assets and intellectual property of Alzex Biomedical Group Inc. ("Alzex Bio"), a company incorporated under the laws of the Province of British Columbia, Canada. The purchase price was 10,000,000 restricted shares of our Series A and Series B Convertible Preferred Stock, which were subsequently issued on August 5, 2022. The Company will also advance the sum of $150,000 to Alzex Bio to be disbursed with mutual agreement for settlement of certain outstanding liabilities of Alzex Bio as well as to further secure, and refile where warranted, additional patent protection covering the intellectual property. Under the terms of the asset purchase agreement, the shareholders of the Companys Series A and Series B Convertible Preferred Stock will retain security over the intellectual property until we have successfully raised the first five million dollars ($5,000,000 USD) for deployment towards the clinical development of the acquired Alzex Bio assets, at which point the preferred shares will automatically convert to common shares.